Kornimate/medical-research-clean huggingface dataset:
chemoradiotherapy of nsclc stage iiib

Conditions: NSCLC Stage IIIB; Concomitant Radiochemotherapy

Summary: to evaluate the best timing of the concomitant chemoradiotherapy among patients with nsclc stage iii not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.

chemotherapy: c = cisplatine : 80 mg/m² p = paclitaxel : 200 mg/m² n = vinorelbine : 15 mg/m² radiotherapy: 66 gy with 33 fractions (2 gy/fraction, 1 fraction/day, 6,5 weeks) high energy photons x (\>= 9mv)

Eligibility criteria:
inclusion criteria: * nsclc stage iiia n2 or iiib not resectable, except n3 sus-clavicular, nor reached pleural * ps = 0 or 1 * possibility of including all the targets in only one exposure field * slimming \< 10% of the weight of the body * functions hepatic, renal and hematologic normal * vems \>40% and pao2 \>60 mmhg * written and signed informed consent exclusion criteria : - nsclc stage iv or wet-iiib
effects of general anesthesia and spinal-morphine anesthesia on recovery and comfort after benign abdominal hysterectomy

Conditions: Hysterectomy (MeSH nr: E04.950.300.399)

Summary: the purpose of this study is to determine whether spinal anesthesia combined with intrathecal morphine in abdominal hysterectomy on benign gynecological indications gives better outcome concerning duration of hospital stay and postoperative patient comfort than general anesthesia.


Eligibility criteria:
inclusion criteria: * female between 18 and 60 years of age. * scheduled for abdominal hysterectomy - total or subtotal -on benign gynecological indication. * at least one ovary planned to be preserved at the hysterectomy. * can understand and communicate in swedish * accept participation after written and verbal information and after signed informed consent. * has supervision at home after discharge from hospital during the first couple of days and has access to a telephone. exclusion criteria: * contra-indications against spinal or general anesthesia or the standard dosage of the study drugs * asa classification ≥ class 3 * postmenopausal women without hrt (hormone replacement therapy). * suspected gynecological malignancy * previously undergone bilateral oophorectomy * substantial physically disabled so that a normal recovery with early physical mobilization can not be anticipated. * mentally or severly psychic disabled

Keywords: hospitalization postoperative care quality of life health economy anesthesia. spinal anesthesia, general
effect of denileukin diftitox on immune system in ctcl patients

Conditions: Cutaneous T-cell Lymphoma; Sezary Syndrome; Mycosis Fungoides

Summary: this is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. patients who are undergoing standard of care therapy with denileukin diftitox will be invited to participate. blood and tissue samples will be obtained at baseline, day 5 and day 19 in up to the first 4 cycles of denileukin diftitox.

although the etiology of ctcl is not fully understood, it is believed to be a malignancy proliferation of a "memory" t-cell in the context of th2-type cytokine profile and suppressed cytotoxic t-cell (ctl) immunity. t-regulatory (t-regs) cells may be important in ctcl in the setting of immunotherapy. removal of t-regs would result in enhanced immune responses in vitro, which may translate into augmentation of the anti-tumor immune response and durable clinical responses in vivo. we propose to evaluate effects of ontak on the t-reg cell subset in patients undergoing routine therapy with ontak. we will evaluate t-reg subsets in peripheral blood and tumor tissues from the patients both phenotypically using multi-color facs analysis and confocal microscopy, and functionally in mlrs and elispot assays with baseline, day 5 and 19 blood samples in up to four cycles. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
inclusion criteria: * 18 and older * diagnosed with ctcl * able and willing to provide informed consent * will be receiving denileukin diftitox per standard guidelines exclusion criteria: * prior history of receiving ontak * pregnancy

Keywords: cutaneous t-cell lymphoma sezary syndrome mycosis fungoides denileukin diftitox
propofol versus the use of dexmedetomidine as a sedative agent for colonosopy

Conditions: Colonic Diseases

Summary: dexmedetomidine as a sedative agent for patients presented for lower gastrointestinal endoscopy

propofol versus the use of dexmedetomidine as a sedative agent for patients presented for lower gastrointestinal endoscopy

Eligibility criteria:
inclusion criteria: * aged 25-45 years, * asa class i or ii, * who are scheduled for elective outpatient colonoscopy exclusion criteria: * refused to give informed consent * if they had known hypersensitivity to the used drugs * patients with morbidly obese patients * patients with increased risk for airway obstruction as obstructive sleep apnea, * liver diseases
the association of costimulatory molecules and ppar-polymorphisms with autoimmune thyroid disease in taiwan

Conditions: AITd Patients With Different Polymorphisms

Summary: autoimmune thyroid disease is the most common organ-specific autoimmune disease. aitd include graves' disease and hashimoto's thyroiditis. although the pathogenesis of aitd remains unclear, it is generally thought that the mechanisms of the disease is a complex disease in which susceptibility genes and environmental triggers act in concert to initiate the autoimmune response to the thyroid. the initial step of thyroid autoimmunity is the activation of t cells. the activation of t cell requires two signals: firstly, thyroid follicular cells or antigen presenting cells binds to t cell receptor through antigenic hla complex. secondly, the activation of t cells is also required the interaction of costimulatory molecules between thyroid follicular cells and immune cells, including ctla-4, cd 40, cd28, icos. ppar- is a kind of intranuclear transcription factor, associated with adipogenesis and inflammation. some reports showed that ppar- polymorphism may have a protective effect from graves' ophthalmopathy. the goal of the study is to investigate the relationship among snp and mrna of costimulatory molecules and ppar- , serum cytokine including tnf- and sil-2r, and clinical characteristics in aitd patients. from the study, we hope to clarify the role of costimulatory molecules and ppar- polymorphism in aitd.

autoimmune thyroid disease is the most common organ-specific autoimmune disease. aitd include graves' disease and hashimoto's thyroiditis. although the pathogenesis of aitd remains unclear, it is generally thought that the mechanisms of the disease is a complex disease in which susceptibility genes and environmental triggers act in concert to initiate the autoimmune response to the thyroid. the initial step of thyroid autoimmunity is the activation of t cells. the activation of t cell requires two signals: firstly, thyroid follicular cells or antigen presenting cells binds to t cell receptor through antigenic hla complex. secondly, the activation of t cells is also required the interaction of costimulatory molecules between thyroid follicular cells and immune cells, including ctla-4, cd 40, cd28, icos. ppar- is a kind of intranuclear transcription factor, associated with adipogenesis and inflammation. some reports showed that ppar- polymorphism may have a protective effect from graves' ophthalmopathy. the goal of the study is to investigate the relationship among snp and mrna of costimulatory molecules and ppar- , serum cytokine including tnf- and sil-2r, and clinical characteristics in aitd patients. from the study, we hope to clarify the role of costimulatory molecules and ppar- polymorphism in aitd.

Eligibility criteria:
inclusion criteria: * autoimmune thyroid patients * patients who cut nodular goiter in wanfang hospital exclusion criteria: * none

Keywords: autoimmune thyroid disease
stereotactic radiosurgery using cyberknife in treating women with advanced or recurrent gynecological malignancies

Conditions: Fallopian Tube Cancer; Ovarian Sarcoma; Ovarian Stromal Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Uterine Sarcoma; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Uterine Sarcoma; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IV Endometrial Carcinoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Uterine Sarcoma; Stage IV Vulvar Cancer; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer

Summary: rationale: stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. purpose: this clinical trial studies stereotactic radiosurgery using cyberknife works in treating women with advanced or recurrent gynecological malignancies.

primary objectives: i. the primary goal of this study is to estimate the rate of grade 3 or higher acute toxicities observed during a 6 month period following cyberknife radiosurgery for gynecologic cancers. ii. to evaluate clinical response to radio-surgery for gynecologic tumors. iii. to assess general and site specific quality of life (using sf-12, fact-en, fact-o, fact-cx or fact-v) and to evaluate patient's level of pain. secondary objectives: i. as a secondary objective, toxicities during the 2 years following cyberknife radiosurgery will also be described. outline: patients undergo 3 fractions of cyberknife stereotactic radiosurgery. after completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.

Eligibility criteria:
inclusion * pathologically proven gynecologic malignancy * no prior cryosurgery or radiofrequency ablation, in target lesion * patient is able to give and sign study specific informed consent * measurable disease, according to recist criteria * laboratory parameters and appropriate clearance from anesthesia based on other medical co-morbidities for placement of fiducials; these would include cbc, basic metabolic panel, bun, and creatinine * \>= 4 weeks from previous treatment (chemotherapy or radiation) of malignancy * ecog performance status of 0-3 as this procedure is minimally invasive and considered palliative in these patients exclusion * any patient with active connective tissue disease such as lupus or dermatomyositis is excluded * any patient with active crohn's disease or active ulcerative colitis is excluded * major medical or psychiatric illness, which would prevent completion of treatment or interfere with follow-up is excluded
special drug use investigation for imuran (azathioprine) tablet (pulmones transplantation)

Conditions: Liver Diseases

Summary: this post-marketing surveillance study is to investigate the efficacy and safety of azathioprine tablets in subjects whom lung transplantation is performed.


Eligibility criteria:
inclusion criteria: * subjects who undergo lung transplantation and azathioprine tablets were administered exclusion criteria: * subjects with hypersensitivity to the ingredients of azathioprine tablet * subjects who is pregnant or might be pregnant * subjects whose white count is lower than 3000/cubic millimeter

Keywords: antirejection
sequential therapy for hypogonadotropic hypogonadism

Conditions: Hypogonadotropic Hypogonadism; Kallmann Syndrome

Summary: the traditional therapy for induction of spermatogenesis in male hypogonadotropic hypogonadism requires both hcg and human menopausal gonadotropin (hmg) or fsh until pregnancy occurs. because of the high cost of hmg or fsh preparations and poor compliance, the investigators raise a new sequential therapeutic approach which can make the treatment more economic and tolerable. the zinc supplement will be also evaluated in patients in this study. this randomized, parallel, open, and multi-center study will compare the efficacy of traditional therapy with new therapy and evaluate the safety of the new protocol.


Eligibility criteria:
inclusion criteria: * clinical hypogonadotropic hypogonadism * hormonal levels: testosterone \< 1.8ng/ml, lh \< 2-3 miu/ml and fsh \< 2-3 miu/ml * infantile testis * delayed bone age * normal testing of the anterior pituitary gland exclusion criteria: * prior therapy with hmg or fsh * severe dysfunction of live and kidney * cryptorchidism or no response to hcg stimulation experiment (testosterone \< 1.8ng/ml after hcg stimulation) * another pituitary hormonal deficiency * hypergonadotropic hypogonadism * with abnormal karyotype

Keywords: hypogonadotropic hypogonadism kallmann syndrome lh fsh
novel coating to minimize bacterial adhesions and tooth wear in denture acrylic

Conditions: Denture Stomatitis; Wear of Denture Teeth

Summary: this study evaluates the effect of coatings on bacterial adhesion on denture acrylic and the wear of denture teeth.

denture stomatitis is a prevalent disease among removable denture wearers. the cause of this disease stems from a myriad of factors including host immunity and poor oral hygiene. denture acrylic material is very conducive for the growth and adhesion of bacteria because of its porous nature. the application of plasma enhanced chemical vapor deposited (pecvd) coatings on the surface of acrylic dentures can produce a less porous surface which may minimize the adhesion of bacteria and therefore colonization. the goal is the application of these coatings will help minimize the occurrence of denture stomatitis. another issue of removable dentures is the low wear resistance of denture teeth. the application of these coatings on denture teeth should minimize wear of these teeth and prolong the life of removable dentures.

Eligibility criteria:
inclusion criteria: * patients who are missing some teeth and will need removable dentures exclusion criteria: * medical contraindication for dental treatment
study of fyu-981 in hyperuricemic outpatients with or without gout (effect on two hyperuricemic types)

Conditions: Hyperuricemia With or Without Gout

Summary: to investigate the pharmacodynamics and safety of fyu-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.


Eligibility criteria:
inclusion criteria: * serum urate level: * \>= 7.0mg/dl in patients with gouty nodule or with history of gout, or \>=8.0mg/dl in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dl * disease type in the classification of hyperuricemia: uric acid-overproduction type or uric acid-underexcretion type * outpatients exclusion criteria: * gouty arthritis within 14 days before randomized allocation
systane® balance symptoms (osdi) & inflammatory biomarkers

Conditions: Dry Eye Syndrome

Summary: the purpose of this study is to evaluate the ability of systane® balance and systane® gel to improve comfort in subjects with dry eyes.


Eligibility criteria:
inclusion criteria: * read, sign, and date the informed consent document; * must not have used any topical ocular drops for approximately 24 hours prior to visit 1; * meet the protocol-specified dry eye criteria at screening visit (visit 1); * intraocular pressure (iop) less than or equal to 22 millimeters of mercury (mmhg) in both eyes; * other protocol-defined inclusion criteria may apply. exclusion criteria: * history or evidence of ocular or intraocular surgery or serious trauma in either eye within the past 6 months; * current punctal occlusion of any type (e.g., collagen plugs, silicone plugs); * history or evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye; * use of any concomitant topical ocular medications during the study period; * currently using restasis but unwilling to discontinue its use 1 month prior to screening and for the entire study period; * use of systemic medications that may contribute to dry eye unless on a stable dosing regimen for a minimum of 30 days prior to visit 1 and that remains stable throughout the study; * uncontrolled ocular conditions such as uveitis, glaucoma or any other ocular condition that may preclude the safe administration of either drop under investigation; * other protocol-defined exclusion criteria may apply.

Keywords: dry eye lipid deficiency inflammatory markers
study evaluating the performance and safety of global d implants indicated for trauma surgery (cmf-trauma)

Conditions: Trauma Injury; Maxilla Fracture; Maxillofacial Trauma

Summary: this study is set up within the framework of the european union regulation 2017/745 on medical devices. its objective is to confirm the performance and safety of the global d implants (ortrautek® and minitek/microtek®) used for trauma surgery.

study design : non-interventional, prospective, multicentric, national, open-label, non-comparative study. investigators : at least 6 sites in france. a statistical evaluation will be performed on those data in order to determine the performance and the security of those devices.

Eligibility criteria:
inclusion criteria: * male or female patient, major or minor (11 years old minimum) * patient having first facial trauma surgery (maxillary, mandibular or maxillomandibular fractures with/without annex skull's or face's fractures) * patient with abilities to read, understand and answer to the study questionnaires. * patient (and his legal representative if minor) who signed the study consent form. * patient affiliated to a social security system. exclusion criteria: * patient allergic to one of the components of the implants * patient with physical or mental inabilities that will compromise the follow-up during the study * patient with acute or chronic infection (local or systemic) * patients with bone's tumors in the anchorage area of the implant * person on legal protection * pregnant or breastfeeding women

Keywords: performance safety screw plate medical device trauma surgery cranio-maxillofacial global d
foot disorders in x-linked hypophosphatemia

Conditions: X-linked Hypophosphatemia

Summary: this study aimed to characterize foot pathologies using x-rays and clinical examination and assess related outcome scores in adolescents and adults with x-linked hypophophatemia

a single center, cross-sectional analysis of adolescent and adult patients with xlh with and without previous surgical intervention was performed at the orthopaedic hospital speising, vienna, austria. clinical examination, quality of life questionnaires and radiographic data of foot x-rays in standing position were collected. radiographic evaluation was performed to analyze foot deformity as well as signs of osteoarthritis at the foot.

Eligibility criteria:
inclusion criteria: - patients with confirmed xlh, ≥ 16 years were invited to participate in this study exclusion criteria: * exclusion criteria were other forms of hypophosphatemia, pregnancy and recent lower limb surgery within 3 months.

Keywords: foot and ankle
safety study of pegylated interferon lambda plus single or 2 direct antiviral agents with ribavirin

Conditions: Hepatitis C

Summary: the purpose of this study is to determine if combination therapy with pegylated interferon lambda (bms-914143) plus ribavirin (rbv) with a single direct antiviral agent (bms-790052 or bms-650032) for 24 weeks is effective and safe for treatment of chronic hepatitis c (chc) compared to current standard therapy with pegylated interferon alpha-2a plus rbv for 48 weeks.

study classification: pharmacokinetics/ pharmacodynamics

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * chronic hepatitis c, genotype 1 * hcv rna \>100,000 iu/ml at screening; * seronegative for human immunodeficiency virus (hiv) and hepatitis b surface antigen (hbsag); * liver biopsy within prior 2 years; subjects with compensated cirrhosis can enroll and will be capped at approximately 10% exclusion criteria: * any evidence of liver disease other than hcv; * co-infection with hiv; * diagnosed or suspected hepatocellular carcinoma; * medical history or laboratory value abnormalities that would prohibit the use of pegylated interferon alpha-2a or ribavirin
prevention of coronary slow flow or no-reflow during epci in patients with acute stemi

Conditions: ST Segment Elevation Myocardial Infarction; Elective Percutaneous Coronary Intervention

Summary: elective percutaneous coronary intervention (epci) is the common treatment of st segment elevation myocardial infarction (stemi).slow flow / no-reflow phenomenon following epci in stemi patients has been a serious and common complication that closely related to the incidence of major adverse cardiovascular events (mace) and affected patients' prognosis. no reflow is a multi-factorial phenomenon. and its preventive and therapeutic effects are not satisfactory. this prospective randomized controlled study aimed to compare favorable effects of nitroprusside versus tirofiban on the prevention of slow flow / no-reflow phenomenon during epci.


Eligibility criteria:
inclusion criteria: * ischemic symptoms \ 24 hours) * continued ischemic chest pain \> 30min * st-segment elevation ≥ 0.1 millivolt in 2 or more contiguous leads on the 12-lead ecg or new left bundle branch block (lbbb) * detection of a rise of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (url) * elective coronary artery angiography was planned. exclusion criteria: * emergency thrombolytic therapy was performed before elective coronary artery angiography * cardiogenic shock with no response to hypervolemic treatment or vasopressor * severe cardiomyopathy or valvular disease requiring intervention * coronary ectasia * severe heart failure * contraindication or allergy to antiplatelet drugs * contraindication or allergy to experimental drugs * unable to receive at least 1 year of dual antiplatelet therapy * active bleeding or extreme-risk for major bleeding * severe liver or renal failure * life expectancy \< 1 year * unable or unwilling to provide informed consent * women of child bearing potential * under 18 years of age * hemoglobin \< 90g/l * platelet count \< 100×10\^9/l * can not cooperate (with mental disorders or cognitive disorders)

Keywords: prevention slow flow no reflow nitroprusside tirofiban